MSG1 and its related protein MRG1 share a transcription activating domainTranscriptional activating activity of Smad4: roles of SMAD hetero-oligomerization and enhancement by an associating transactivatorWhat can article-level metrics do for you?ORCID: a system to uniquely identify researchersKey Issue Collective Action for the Open Researcher & Contributor ID (ORCID)ORCID: Unique Identifiers for Authors and ContributorsImatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST).An analysis of Wikipedia references across PLOS publicationsEuropean consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I.Chemotherapy for breast cancer brain metastases.Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer.European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II.Erythropoietin in cancer-related anemia.Recommendation of: ORCID Works Metadata Working GroupPreclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study.Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18.Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia.PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro.Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer.Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer.Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05)Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells.Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas.Retrospective analyses of patient characteristics having predictive impact on survival under everolimus.Complete cytogenetic remission after decitabine treatment in a patient with secondary AML harbouring high p15INK4b gene methylation and high global DNA methylation.The Scholix Framework for Interoperability in Data-Literature Information ExchangeRegulation of expression of MSG1 melanocyte-specific nuclear protein in human melanocytes and melanoma cells.MSG1 (melanocyte-specific gene 1): mapping to chromosome Xq13.1, genomic organization, and promoter analysis.Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients.Altmetrics in Evolution: Defining and Redefining the Ontology of Article-Level MetricsThe many faces of article-level metricsA Data Citation Roadmap for Scholarly Data RepositoriesCode of practice for research data usage metrics release 1Code of practice for research data usage metrics release 1Corrigendum to: “European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I” [Eur Urol 2008;53:478–96] and to: “European ConseEverolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study GroupReference ManagementLetter from the Guest Content Editor: Altmetrics Have Come of AgePlosOpenR – Exploring FP7 funded PLOS publications
P50
P664
P710
Q24321610-B1BDFAEF-8E4E-4C5E-8C55-94ED5DA489E7Q24324502-52812BF6-6194-4D12-9DB7-6CDBDEC02A86Q28662254-D864E1C2-45CF-4A74-9708-A4EDCFE3C0BBQ30512726-B4AC8F2C-AB4D-4042-9BBA-B1DD951E9CCCQ30557287-2326D58F-6262-4D42-907C-22F3DEDB777AQ30557288-63e3aeb3-47c8-1719-a611-84a0dcb06de2Q34276167-CB9623AE-FAB7-4AF7-8A20-2A6AEBAC92ACQ34637168-9d703dcd-4b77-bc76-3b93-8e1504f92693Q34735176-AFD9F4E8-1726-4D8F-B7AC-1B8FC05F1395Q34988195-90C6946F-4F64-4C02-91A7-17D6393DE4ECQ35623265-FBC15FC2-E7CE-4D4E-92F4-9BB44DB01FA4Q36187022-6633B04D-FB90-44F7-AE46-C0A244D00673Q37055475-93EA1D3E-0482-4C01-9C7E-BDBB436591C0Q37289165-30D20A88-0E13-43E4-8237-4517B6BD0D89Q38908957-a44c64c8-44cc-cf7c-e651-4b76e561f91dQ39574471-759620D8-4F2B-4AE3-B1DC-341128A05BA5Q40332094-EBE328D0-6599-44E2-A1AA-AF589F151136Q40562864-BB745554-58A2-43D1-BBC0-DCDF2DD7E0D4Q40643478-05C59F6E-12F9-4CD7-AFAC-FAFF4194721AQ43129844-9D649CC3-0753-4EBA-ACFF-047FEAAF0906Q43223621-6C88C393-FF21-4453-A8EA-FEBA84F751F7Q43718098-63101AB2-C951-427E-B769-274BCF219806Q44108050-F0999D77-33AC-4788-A9D0-0CE6CECB0645Q44700024-CAA88D65-22DA-4E13-B620-CC0772F40D0BQ45215346-BCB143EB-C8F6-4CE0-923A-10A740C984A0Q46428509-6DB75934-7BA5-44B4-9B4C-0B9381D4B445Q47090479-AAB51DBF-EF93-4EB2-A4B8-80958885CE6FQ47769214-6C66175B-B151-4225-B3B2-AC20A33B512AQ48027596-9B0D19A1-6560-4E32-A494-F9A8A03FA0AFQ54618206-11FA8458-94AC-4F49-826E-7222FF310EC9Q56481014-0871F5D0-B979-41D5-B150-086384C02B21Q56567820-C554B056-0519-4278-8C74-5D367F459EF9Q56875641-262A5B90-09DE-4F86-A316-936F62595C5DQ57566410-4809891C-BC19-4A44-8D7C-5B21718B48EEQ57566413-2FCC88E3-56BE-4442-9069-06B70B6DB89DQ57575120-C1E794EE-1FEE-488C-ACB0-1B5EACBA1A36Q57837577-682E6D83-F142-4600-9C1C-99477FBC539FQ57837626-05CA7507-85DC-4751-8662-1EBB2DA32E57Q57837631-F53650B9-537F-4B83-90D4-7ECF13F748DBQ57837643-1810EA80-DD6F-4AA2-8907-E08E81D765C3
P50
description
German researcher and open science advocate
@en
onderzoeker
@nl
name
Martin Fenner
@af
Martin Fenner
@an
Martin Fenner
@ast
Martin Fenner
@bar
Martin Fenner
@br
Martin Fenner
@ca
Martin Fenner
@co
Martin Fenner
@cs
Martin Fenner
@cy
Martin Fenner
@da
type
label
Martin Fenner
@af
Martin Fenner
@an
Martin Fenner
@ast
Martin Fenner
@bar
Martin Fenner
@br
Martin Fenner
@ca
Martin Fenner
@co
Martin Fenner
@cs
Martin Fenner
@cy
Martin Fenner
@da
altLabel
M Fenner
@en
MH Fenner
@en
Martin H. Fenner
@en
Martin Hellmut Fenner
@en
prefLabel
Martin Fenner
@af
Martin Fenner
@an
Martin Fenner
@ast
Martin Fenner
@bar
Martin Fenner
@br
Martin Fenner
@ca
Martin Fenner
@co
Martin Fenner
@cs
Martin Fenner
@cy
Martin Fenner
@da
P214
P227
P106
P1153
7006600825
P2002
P2037
P21
P213
0000 0003 5060 549X
P214
P227
1017967067
P2456
P31
P373
Martin Fenner
P4012
P4411
Martin-Fenner
P496
0000-0003-1419-2405